Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
Oncologist
; 26(11): e2053-e2060, 2021 11.
Article
in En
| MEDLINE
| ID: mdl-34313371
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Gastrointestinal Stromal Tumors
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Oncologist
Journal subject:
NEOPLASIAS
Year:
2021
Type:
Article
Affiliation country:
Australia